Detection Kit for Noninvasive Fetal Trisomy（T21, T18, T13）Test
- UID
- IMP/IVD/2021/000481_057f2bbc2966701510d293018ec2ddd9_d5e2a2721708347c3989a5f6f6b6fae3
- Device class
- Class C
- Brand name
- Combinatorial Probe-Anchor Synthesis Sequencing Method
- License holder
- Rivaara Labs Private Limited
- Approving authority
- CDSCO
- Product information
- For in vitro diagnostic use only. This kit is to prenatally assessing the fetal risk of Down syndrome (Combinatorial Probe-Anchor Synthesis Sequencing Method), Edwards syndrome (Combinatorial Probe-Anchor Synthesis Sequencing Method) and Patau syndrome (Combinatorial Probe-Anchor Synthesis Sequencing Method) in high-risk pregnant women with more than 12 weeks of pregnancy. This is achieved through analyzing the differences in the number of chromosomes 21, 18 and 13 in the cell-free fetal DNA in maternal plasma samples, to perform prenatal screening for trisomies of chromosomes 21, 18 and 13 (Combinatorial Probe-Anchor Synthesis Sequencing Method). This kit is used to prepare a sequencing DNA library of cell free DNA. This kit shall be used according to industry norms
Detection Kit for Noninvasive Fetal Trisomy（T21, T18, T13）Test is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2021/000481_057f2bbc2966701510d293018ec2ddd9_d5e2a2721708347c3989a5f6f6b6fae3. This device is marketed under the brand name Combinatorial Probe-Anchor Synthesis Sequencing Method. The license holder is Rivaara Labs Private Limited, and it is classified as Device Class Class C. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.